Filing Details

Accession Number:
0001415889-23-000875
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-01-12 16:30:25
Reporting Period:
2023-01-10
Accepted Time:
2023-01-12 16:30:25
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1650664 Editas Medicine Inc. EDIT Biological Products, (No Disgnostic Substances) (2836) 464097528
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1755098 Michelle Robertson C/O Editas Medicine, Inc.
11 Hurley St.
Cambridge MA 02141
Evp, Chief Financial Officer No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2023-01-10 1,752 $8.16 80,530 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
Footnotes
  1. Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on December 30,2019, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on January 9,2023. The sale does not represent a discretionary trade by the Reporting Person.
  2. This transaction was executed in multiple trades at prices ranging from $8.1600 to $8.1911. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request, to the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.